个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Chen Xue-Li[1] ; Fu Yan-Jing[2] ; Qu Bo[3] ; Wang Ye-Wei[4] ; Tang Xin[5] ; Wang Yu-Hong[6] ; Zhou Guo-Yi[7] ; Lin Ming-Kai[8] ; Shen Jing-Yuan[9] ; Yao Jin[10] ; Li Su-Yan[11] ; Wu Miao-Qin[12] ; Peng Hua-Zong[13] ; Lai Ming-Ying[14] ; Wu Ren-Yi[15] ; Zhang Yi-Nong[16] ; Li Yan[17] ; Wu Xiao-Jun[18] ; Zhang Ming-Chang[19] ; Guo Su-Ping[20] ; Sun Xing-Huai[1,*1] ;
机构： [1]Department of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai 200000, China [2]Department of Ophthalmology, Daqing Ophthalmologic Hospital, Daqing 163000, Heilongjiang Province, China [3]Department of Ophthalmology, the Fourth Affiliated Hospital of China Medical University, Shenyang 110000, Liaoning Province, China [4]Department of Ophthalmology, Da Lian He Eye Specialist Hospital, Dalian 116000, Liaoning Province, China [5]Department of Ophthalmology, Beijing Tongren Hospital, Beijing 100000, China [6]Department of Ophthalmology, Xiamen Eye Center of Xiamen University, Xiamen 361000, Fujian Province, China [7]Department of Ophthalmology, Yueqing People’s Hospital, Wenzhou 325600, Zhejiang Province, China [8]Department of Glaucoma, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510000, Guangdong Province, China [9]Department of Ophthalmology, Shengzhou Shen’s Eye Hospital, Shaoxing 312400, Zhejiang Province, China [10]Department of Ophthalmology, the Affiliated Eye Hospital of Nanjing Medical University, Nanjing 210000, Jiangsu Province, China [11]Department of Ophthalmology, Xuzhou No.1 Peoples Hospital, Xuzhou 221000, Jiangsu Province, China [12]Department of Ophthalmology, Zhejiang Provincial People’s Hospital, Hangzhou 310000, Zhejiang Province, China [13]Department of Ophthalmology, Wuhan Eyegood Ophthalmic Hospital, Wuhan 430014, Hubei Province, China [14]Department of Ophthalmology, Shenzhen Eye Hospital, Shenzhen 518001, Guangdong Province, China [15]Department of Glaucoma, Shanghai Heping Eye Hospital, Shanghai 200000, China [16]Department of Ophthalmology, Wuxi Second People’s Hospital, Wuxi 214000, Jiangsu Province, China [17]Department of Ophthalmology, First Affiliated Hospital of Kunming Medical University, Kunming 650000, Yunnan Province, China [18]Department of Ophthalmology, Union Shenzhen Hospital (Nanshan Hospital), Shenzhen 518000, Guangdong Province, China [19]Department of Ophthalmology, Wuhan Union Hospital, Wuhan 430000, Hubei Province, China [20]Department of Ophthalmology, Shengyang He Eye Specialist Hospital, Shenyang 110000, Liaoning Province, China
出处：
DOI： 10.18240/ijo.2023.01.16
ISSN：

关键词： tafluprost glaucoma ocular hypertension intraocular pressure adverse drug reactions

摘要：
To investigate the treatment pattern and safety of tafluprost for glaucoma and ocular hypertension (OH) in clinical practice in China.This post-marketing observational study included patients who received tafluprost to lower intraocular pressure (IOP) within 30d between September 2017 and March 2020 in 20 hospitals in China. Adverse drug reactions (ADRs) during tafluprost treatment and within 30d after the treatment were collected.A total of 2544 patients were included in this study, of them 58.5% (1488/2544) had primary open angle glaucoma (POAG), 21.9% (556/2544) had OH and 19.7% (500/2544) used tafluprost for other reasons. Of 359 ADRs occurred in 10.1% (258/2544) patients, and no serious adverse event occurred. The most common ADR was conjunctival hyperemia (128 ADRs in 124 patients, 4.9%). Totally 1670 participants (65.6%) combined tafluprost with carbonic anhydrase inhibitors (CAIs; 37.1%, 620/1670), sympathomimetics (33.5%, 559/1670), β-blockers (33.2%, 555/1670), other prostaglandin analogs (PGAs; 15.6%, 260/1670) and other eye drops (15.1%, 253/1670). The highest incidence of conjunctival hyperemia was noted in patients who received tafluprost in combination with other PGAs (23 ADRs in 23 patients, 8.8%, 23/260) and the lowest was in combination with CAIs (16 ADRs in 16 patients, 2.6%, 16/620). Tafluprost was applied in primary angle-closure glaucoma (41.6%, 208/500), after glaucoma surgery (17.8%, 89/500) and after non-glaucoma surgery (15.8%, 79/500).Tafluprost is safe for POAG and OH, and tolerable when combined with other eye drops and under various clinical circumstances.International Journal of Ophthalmology Press.

基金：
Supported by Santen Pharmaceutical (China) Co., Ltd.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 4 区 医学
小类 | 4 区 眼科学
JCR分区：
出版当年[2023]版：
Q2 OPHTHALMOLOGY
最新[2023]版：
Q2 OPHTHALMOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai 200000, China
通讯作者：
通讯机构： [1]Department of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai 200000, China [*1]Department of Ophthalmology, Eye & ENT Hospital of Fudan University, Shanghai 200000, China.
推荐引用方式(GB/T 7714)：
Chen Xue-Li,Fu Yan-Jing,Qu Bo,et al.Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study[J].INTERNATIONAL JOURNAL OF OPHTHALMOLOGY.2023,16(1):108-114.doi:10.18240/ijo.2023.01.16.
APA：
Chen Xue-Li,Fu Yan-Jing,Qu Bo,Wang Ye-Wei,Tang Xin...&Sun Xing-Huai.(2023).Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study.INTERNATIONAL JOURNAL OF OPHTHALMOLOGY,16,(1)
MLA：
Chen Xue-Li,et al."Safety profile of 0.0015% tafluprost eye drops in China: a post-marketing observational study".INTERNATIONAL JOURNAL OF OPHTHALMOLOGY 16..1(2023):108-114

相关文献

[1]Effectiveness and safety of tafluprost in primary open-angle glaucoma and ocular hypertension: a post-marketing phase IV study in China [2]c-Jun N-terminal kinase 3 expression in the retina of ocular hypertension mice: a possible target to reduce ganglion cell apoptosis [3]Effect of Epstein-Barr Virus on Macrophage M2/M1 Migration and EphA2 Expression in Adverse Drug Reactions [4]青光眼合并白内障的手术治疗研究进展 [5]Effect of type 2 diabetes mellitus on visual field defect, retinal nerve fiber layer (RNFL) thickness and intraocular pressure index in patients with primary open angle glaucoma [6]新生血管性青光眼视乳头筛板结构的研究 [7]Exploration of associations between adverse drug reactions and clinical outcomes in anlotinib treatment against medullary thyroid carcinoma (MTC): A subgroup analysis based on the ALTER01031 trial. [8]Machine learning identifying peripheral circulating metabolites associated with intraocular pressure alterations. [9]Six Year Incidence and Risk Factors for Primary Open Angle Glaucoma and Ocular Hypertension: The Singapore Epidemiology of Eye Diseases Study [10]青光眼合并白内障的手术治疗研究进展

资源点击量：53661 今日访问量：0 总访问量：1665 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 昆明医科大学第一附属医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西昌路295号(650032)